TELA Bio, Inc. (NASDAQ:TELA) Insider Ew Healthcare Partners Fund 2, Buys 5,000 Shares

TELA Bio, Inc. (NASDAQ:TELAGet Rating) insider Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock in a transaction that occurred on Wednesday, May 25th. The shares were acquired at an average price of $6.87 per share, with a total value of $34,350.00. Following the acquisition, the insider now directly owns 3,445,709 shares of the company’s stock, valued at approximately $23,672,020.83. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Ew Healthcare Partners Fund 2, also recently made the following trade(s):

  • On Friday, May 27th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The shares were acquired at an average price of $7.43 per share, with a total value of $37,150.00.
  • On Monday, May 23rd, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average price of $8.53 per share, with a total value of $42,650.00.
  • On Friday, May 20th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average price of $8.79 per share, with a total value of $43,950.00.
  • On Wednesday, May 18th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average price of $8.96 per share, with a total value of $44,800.00.
  • On Monday, May 16th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average price of $8.61 per share, with a total value of $43,050.00.
  • On Friday, May 13th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average price of $8.48 per share, with a total value of $42,400.00.
  • On Wednesday, May 11th, Ew Healthcare Partners Fund 2, purchased 5,000 shares of TELA Bio stock. The stock was bought at an average price of $8.82 per share, with a total value of $44,100.00.
  • On Monday, May 9th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average price of $9.38 per share, with a total value of $46,900.00.
  • On Friday, May 6th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average price of $9.55 per share, with a total value of $47,750.00.
  • On Wednesday, May 4th, Ew Healthcare Partners Fund 2, acquired 5,000 shares of TELA Bio stock. The shares were purchased at an average price of $9.53 per share, with a total value of $47,650.00.

Shares of NASDAQ:TELA traded up $0.36 during trading on Friday, hitting $7.36. 48,698 shares of the company were exchanged, compared to its average volume of 34,878. The business’s 50 day moving average is $9.82 and its 200-day moving average is $11.44. The company has a market capitalization of $107.15 million, a P/E ratio of -2.97 and a beta of 1.57. The company has a quick ratio of 3.26, a current ratio of 4.10 and a debt-to-equity ratio of 3.15. TELA Bio, Inc. has a 1-year low of $6.32 and a 1-year high of $16.53.

TELA Bio (NASDAQ:TELAGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.25). TELA Bio had a negative return on equity of 155.13% and a negative net margin of 113.15%. During the same quarter last year, the company earned ($0.56) EPS. As a group, sell-side analysts anticipate that TELA Bio, Inc. will post -2.47 earnings per share for the current year.

Several research analysts have commented on the stock. Zacks Investment Research upgraded shares of TELA Bio from a “sell” rating to a “hold” rating in a research report on Tuesday. JMP Securities restated a “buy” rating and set a $22.00 price objective on shares of TELA Bio in a research report on Tuesday, March 22nd.

A number of hedge funds and other institutional investors have recently bought and sold shares of TELA. Morgan Stanley increased its holdings in TELA Bio by 3,256.9% in the second quarter. Morgan Stanley now owns 6,781 shares of the company’s stock valued at $109,000 after purchasing an additional 6,579 shares during the period. Bank of America Corp DE increased its holdings in TELA Bio by 16.6% in the second quarter. Bank of America Corp DE now owns 7,682 shares of the company’s stock valued at $124,000 after purchasing an additional 1,093 shares during the period. Susquehanna International Group LLP acquired a new stake in TELA Bio in the fourth quarter valued at $254,000. BlackRock Inc. increased its holdings in TELA Bio by 4.1% in the fourth quarter. BlackRock Inc. now owns 22,392 shares of the company’s stock valued at $287,000 after purchasing an additional 886 shares during the period. Finally, State Street Corp boosted its position in TELA Bio by 9.1% during the first quarter. State Street Corp now owns 26,065 shares of the company’s stock valued at $303,000 after acquiring an additional 2,167 shares during the last quarter.

About TELA Bio (Get Rating)

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

See Also

Insider Buying and Selling by Quarter for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.